AI Generated Image
3 buzzy medical breakthroughs that may not be all they’re cracked up to be
New York Post • • health
Key Points:
- The Shield Blood Test, FDA-approved for primary colorectal cancer screening, detects stages 2-4 cancer effectively but has limited sensitivity for stage 1 cancer and precancerous lesions, missing up to 87% of these growths, which undermines its reliability compared to colonoscopy.
- At-home Alzheimer’s blood tests provide accessible biomarker screening but raise concerns due to potential false positives, unclear results, lack of clinical oversight, and emotional distress without proper counseling, with no current prevention or treatment benefits from knowing biomarker status alone.
- GeneSight, a genetic test designed to guide psychiatric medication choices, is criticized by experts for lacking clinical utility, as it cannot replace the necessary trial-and-error process and clinical judgment in prescribing, with the FDA advising cautious interpretation of such pharmacogenomic tests.
![Android Auto 17.6 update rolling out with redesigned logo [Gallery]](https://media-cdn.cashwalklabs.io/https%3A%2F%2Fs3.us-west-2.amazonaws.com%2Fimages.cashwalklabs.io%2F0_admin%2Fnews-ai-images%2F01a05db8-82ba-7268-b94e-0097aa064b94.webp?format=webp&w=120&h=80)
